Substance / Medication

Ibopamine

Overview

Active Ingredient
ibopamine
RxNorm CUI
51253

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma.
Ugahary Luana Cahya, Ganteris Elisabeth, Veckeneer Marc et al. · Am J Ophthalmol · 2006
PMID: 16490513RCT
Ibopamine provocative test and glaucoma: consideration of factors that may influence the examination.
Magacho Leopoldo, Lima Francisco E, Costa Marcelus L et al. · Curr Eye Res · 2004
PMID: 14977521Observational
Ibopamine test and frequency doubling perimetry in early glaucoma diagnosis.
Virno M, Gregorio F D E, Saccucci S et al. · Acta Ophthalmol Scand Suppl · 2002
PMID: 12390125Observational
Post-trabeculectomy hypotension and hypoathalamia: efficacy of treatment with ibopamine eyedrops.
Di Giulio S, De Stefano C, Boccassini B et al. · Acta Ophthalmol Scand Suppl · 2000
PMID: 11235545Observational
Rapid corneal adrenochrome deposition from topical ibopamine in the setting of infectious keratitis.
Bhosai S J, Lin C C, Greene J et al. · Eye (Lond) · 2013
PMID: 23079754Case ReportFull text (PMC)
Pigmented deposits on a Boston keratoprosthesis from topical ibopamine.
Kanoff Justin M, Colby Kathryn · Cornea · 2010
PMID: 20567201Case Report
[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine].
Windisch B K, Iliev M E · Klin Monbl Augenheilkd · 2006
PMID: 16705521Case Report
Early Glaucoma Screening Using the Ibopamine Provocative Test.
Domínguez-Dueñas Francisca, Plaza-Espinosa Leticia, Mundo-Fernández Eva E et al. · J Glaucoma · 2016
PMID: 26709501Other
N-Methyldopamine and ibopamine can prevent chemically-induced oxidative ferroptosis in vitro and in vivo.
Jia Yi-Chen, Hao Xiangyu, Zhu Bao Ting · J Pharmacol Exp Ther · 2025
PMID: 40570548Preclinical
Ibopamine challenge testing becomes negative following successful trabeculectomy surgery.
Landers John, Ullrich Katja, Craig Jamie E · Clin Exp Ophthalmol · 2016
PMID: 26575026Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ibopamine (substance)
SNOMED CT
717169003
UMLS CUI
C0123043
RxNorm CUI
51253

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.